Fatty liver is a disease caused by excessive accumulation of fat in the liver due to long-term ort repeated affection of various causative factors'When the pathogenic factor prevails,the qi is sure to be deficient...Fatty liver is a disease caused by excessive accumulation of fat in the liver due to long-term ort repeated affection of various causative factors'When the pathogenic factor prevails,the qi is sure to be deficient',Therefore,deficiency of the vital-qicontributes greatly to the occurrence of fatty liver.For many years,the author has concentrated ont the treatment of fatty liver with the tonificatioin method,or tonification followed by purgation,or the combination of tonificaytioin with purgation,so as to effectively prevent the liver from being injured by harmful substances ,and to benefit the recovery of fatty liver.The following is a report of his experience in treatment of fatty liver with the combined use of tonification and purgation.展开更多
OBJECTIVE: To observe the curative effect of Huqian Wan on liver and kidney-Yin deficiency knee osteoarthritis(KOA).METHODS: One hundred patients were randomly divided into a treatment(50 patients) and control group(5...OBJECTIVE: To observe the curative effect of Huqian Wan on liver and kidney-Yin deficiency knee osteoarthritis(KOA).METHODS: One hundred patients were randomly divided into a treatment(50 patients) and control group(50 patients). In the treatment group, patients orally took the Chinese medicine Huqian Wan. Control group patients orally took Votalin, 75 mg, once a day, for 8 weeks. The visual analog scale(VAS), Western Ontario and Mc Master University Osteoarthritis Index(WOMAC), and Medical Outcomes Study Short Form 36-Item Health Survey(SF36) were used to evaluate the curative effect before treatment and after 8 and 16 weeks of treatment.RESULTS: VAS and WOMAC scores significantly decreased and SF 36 scores significantly increased after treatment in both groups compared with before treatment(P < 0.05). There were significant differences in VAS, WOMAC, and SF 36 score changes between the two groups at week 16(P < 0.05).There was a significant increase in VAS and WOMAC scores in the control groups(P < 0.05) between weeks 8 and 16, but no significant difference was found in the treatment group(P > 0.05).CONCLUSION: Huqian Wan could effectively improve the clinical symptoms and quality of life in patients with KOA. It could also have a better and longer lasting curative effect without obvious adverse events compared with Votalin.展开更多
Objectives： To investigate the mechanism of Liuwei Dihuang Pill （六味地黄丸, LDP） in treating postmenopausal osteoporosis （PMOP） with Shen （Kidney） yin deficiency. Methods： In this study, 205 cases of PMOP wer...Objectives： To investigate the mechanism of Liuwei Dihuang Pill （六味地黄丸, LDP） in treating postmenopausal osteoporosis （PMOP） with Shen （Kidney） yin deficiency. Methods： In this study, 205 cases of PMOP were divided into the PMOP Shen-yin deficiency group （Group A）, PMOP Shen-yang deficiency group （Group B）, PMOP without Shen deficiency group （Group C）, and control group （Group N）. Real-time polymerase chain reaction （RT-PCR） and Western blot techniques were used to observe the effects of LDP treatment on the cardiotrophin-like cytokine factor 1 （CLCF1）, ankyrin repeat and SOCS box containing 1 （ASB1）, and proldneticin 2 （PROK2） genes and the Janus kinase/signal transducer and activator of transcription （JAK/STAT） signaling pathway. Results： The mRNA （P〈0.05） and protein （P〈0.01） expression levels of the CLCF1 gone in Group A were significantly lower than the corresponding levels in Group N. After LDP treatment for 3 months, the mRNA expression levels of the CLCF1 gone were obviously up-regulated （P〈0.01）. After 6-month treatment, the expression levels of CLCF1 mRNA and protein were significantly up-regulated （both P〈0.01）, and the average bone density of the top femur had significantly increased （P〈0.05）. In vitro, CLCF1 overexpression resulted in a significant increase in the total protein and phosphorylated protein levels of JAK2 and STAT3. Conclusions： The CLCF1 gone is an important gone associated with PMOP Shen-yin deficiency and the therapeutic effects of LDP may be mediated by up-regulation of CLCF1 gone expression and activation of the JAK/STAT signaling pathway.展开更多
目的:探讨消增强骨丸对肝肾阴虚型骨质疏松症患者骨转换标志物的影响。方法:选取80例肝肾阴虚型骨质疏松症患者,随机分成观察组和对照组,每组40例。对照组予以碳酸钙D3片、骨化三醇软胶囊及阿仑膦酸钠片,观察组在对照组的基础上服用消...目的:探讨消增强骨丸对肝肾阴虚型骨质疏松症患者骨转换标志物的影响。方法:选取80例肝肾阴虚型骨质疏松症患者,随机分成观察组和对照组,每组40例。对照组予以碳酸钙D3片、骨化三醇软胶囊及阿仑膦酸钠片,观察组在对照组的基础上服用消增强骨丸,两组均治疗6个月。治疗后比较两组腰椎骨密度(bone mineral density,BMD)、髋部BMD、血清25-(OH)VitD、Ⅰ型胶原羧基端肽β特殊序列(β-C-terminal telopeptide of typeⅠcollagen,β-CTX)、Ⅰ型原胶原氨基端延长肽(propeptide of type 1 procollagen,PINP)、骨碱性磷酸酶(bone specific alkaline phosphatase,BALP)、骨钙素(bone gla protein,BGP)及腰部视觉模拟评分法(visual analogue scale,VAS)评分。结果:两组治疗前腰椎BMD、髋部BMD、25-(OH)VitD、β-CTX、PINP、BALP、BGP、腰部VAS评分之间比较,差异无统计学意义(P>0.05)。治疗后观察组腰椎BMD、髋部BMD、25-(OH)VitD、PINP、BALP、BGP较对照组增高,观察组β-CTX、腰部VAS评分较对照组降低(P<0.05)。结论:消增强骨丸治疗肝肾阴虚型骨质疏松症患者疗效可靠,可以影响骨转换标志物,提高骨密度,缓解患者腰部疼痛症状。展开更多
文摘Fatty liver is a disease caused by excessive accumulation of fat in the liver due to long-term ort repeated affection of various causative factors'When the pathogenic factor prevails,the qi is sure to be deficient',Therefore,deficiency of the vital-qicontributes greatly to the occurrence of fatty liver.For many years,the author has concentrated ont the treatment of fatty liver with the tonificatioin method,or tonification followed by purgation,or the combination of tonificaytioin with purgation,so as to effectively prevent the liver from being injured by harmful substances ,and to benefit the recovery of fatty liver.The following is a report of his experience in treatment of fatty liver with the combined use of tonification and purgation.
基金Supported by Major Special Sci-tech Projects of Zhejiang Province(Study on the Early Diagnosis of Osteoarthritis and Intervention of Traditional Chinese Medicine,No.2012C13017-2)the Program for Zhejiang Leading Team of S&T Innovation(Role of Mmp13 and Admats5 in the TGF-βSignaling Pathway and Pathogenesis of Osteoarthritis,No.2011R50022-01)Key Laboratory of Zhejiang Province(Chinese Medicine Intervention for Bone and Joint Diseases,No.2013E10024)
文摘OBJECTIVE: To observe the curative effect of Huqian Wan on liver and kidney-Yin deficiency knee osteoarthritis(KOA).METHODS: One hundred patients were randomly divided into a treatment(50 patients) and control group(50 patients). In the treatment group, patients orally took the Chinese medicine Huqian Wan. Control group patients orally took Votalin, 75 mg, once a day, for 8 weeks. The visual analog scale(VAS), Western Ontario and Mc Master University Osteoarthritis Index(WOMAC), and Medical Outcomes Study Short Form 36-Item Health Survey(SF36) were used to evaluate the curative effect before treatment and after 8 and 16 weeks of treatment.RESULTS: VAS and WOMAC scores significantly decreased and SF 36 scores significantly increased after treatment in both groups compared with before treatment(P < 0.05). There were significant differences in VAS, WOMAC, and SF 36 score changes between the two groups at week 16(P < 0.05).There was a significant increase in VAS and WOMAC scores in the control groups(P < 0.05) between weeks 8 and 16, but no significant difference was found in the treatment group(P > 0.05).CONCLUSION: Huqian Wan could effectively improve the clinical symptoms and quality of life in patients with KOA. It could also have a better and longer lasting curative effect without obvious adverse events compared with Votalin.
基金Supported by National Natural Science Foundation of China(Nos.81173280,81302995,81403420)Fujian Medical Innovation project(No.2011-CX-30)+1 种基金Science and Technology Department of Fujian Province autonomous non-profit research institutes topics project(No.2011R1038-5)Fujian Academy of Traditional Chinese autonomous topics Project(No.2012fjzyyk-5)
文摘Objectives： To investigate the mechanism of Liuwei Dihuang Pill （六味地黄丸, LDP） in treating postmenopausal osteoporosis （PMOP） with Shen （Kidney） yin deficiency. Methods： In this study, 205 cases of PMOP were divided into the PMOP Shen-yin deficiency group （Group A）, PMOP Shen-yang deficiency group （Group B）, PMOP without Shen deficiency group （Group C）, and control group （Group N）. Real-time polymerase chain reaction （RT-PCR） and Western blot techniques were used to observe the effects of LDP treatment on the cardiotrophin-like cytokine factor 1 （CLCF1）, ankyrin repeat and SOCS box containing 1 （ASB1）, and proldneticin 2 （PROK2） genes and the Janus kinase/signal transducer and activator of transcription （JAK/STAT） signaling pathway. Results： The mRNA （P〈0.05） and protein （P〈0.01） expression levels of the CLCF1 gone in Group A were significantly lower than the corresponding levels in Group N. After LDP treatment for 3 months, the mRNA expression levels of the CLCF1 gone were obviously up-regulated （P〈0.01）. After 6-month treatment, the expression levels of CLCF1 mRNA and protein were significantly up-regulated （both P〈0.01）, and the average bone density of the top femur had significantly increased （P〈0.05）. In vitro, CLCF1 overexpression resulted in a significant increase in the total protein and phosphorylated protein levels of JAK2 and STAT3. Conclusions： The CLCF1 gone is an important gone associated with PMOP Shen-yin deficiency and the therapeutic effects of LDP may be mediated by up-regulation of CLCF1 gone expression and activation of the JAK/STAT signaling pathway.
文摘目的:探讨消增强骨丸对肝肾阴虚型骨质疏松症患者骨转换标志物的影响。方法:选取80例肝肾阴虚型骨质疏松症患者,随机分成观察组和对照组,每组40例。对照组予以碳酸钙D3片、骨化三醇软胶囊及阿仑膦酸钠片,观察组在对照组的基础上服用消增强骨丸,两组均治疗6个月。治疗后比较两组腰椎骨密度(bone mineral density,BMD)、髋部BMD、血清25-(OH)VitD、Ⅰ型胶原羧基端肽β特殊序列(β-C-terminal telopeptide of typeⅠcollagen,β-CTX)、Ⅰ型原胶原氨基端延长肽(propeptide of type 1 procollagen,PINP)、骨碱性磷酸酶(bone specific alkaline phosphatase,BALP)、骨钙素(bone gla protein,BGP)及腰部视觉模拟评分法(visual analogue scale,VAS)评分。结果:两组治疗前腰椎BMD、髋部BMD、25-(OH)VitD、β-CTX、PINP、BALP、BGP、腰部VAS评分之间比较,差异无统计学意义(P>0.05)。治疗后观察组腰椎BMD、髋部BMD、25-(OH)VitD、PINP、BALP、BGP较对照组增高,观察组β-CTX、腰部VAS评分较对照组降低(P<0.05)。结论:消增强骨丸治疗肝肾阴虚型骨质疏松症患者疗效可靠,可以影响骨转换标志物,提高骨密度,缓解患者腰部疼痛症状。
